Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Medicaid Health Plans Provide Cost Savings To States And High Quality And Value To Beneficiaries, New Analysis Shows
Medicaid health plans are producing cost savings for states, increasing access to services for individuals covered by Medicaid, improving quality of care, and earning high satisfaction ratings from enrollees, according to a Lewin Group report released today by America"s Health Insurance Plans (AHIP). Twenty-four existing studies were analyzed by the Lewin Group to determine the savings achieved when states have implemented private Medicaid health plans.

Traumatic Brain Injury Treated By Alzheimer's Disease Drug
The destructive cellular pathways activated in Alzheimer"s disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that novel therapy might successfully target both conditions.
News of the day
Global Health Programmes Improve Specific Health Outcomes But Can Constrain Health Systems Of Poor Countries
The emergence of global health initiatives (GHIs), eg, The Global Fund and PEPFAR, has resulted in a striking expansion of key health interventions in recent years, from which millions have benefited. There is also evidence, however, that such initiatives can constrain the health systems of poor countries and that many opportunities to improve efficiency, equity, value for money and outcomes in global public health are still being missed. The health systems strengthening agenda needs more investment, and to be infused with the same sense of ambition and speed that has characterised GHIs. This is one of five key recommendations in a new multi-partner report published in a Health Policy paper in this week"s edition of The Lancet.
Nutrition

Democrat Bill, FTC Examine Ways To Drive Down Health Care Costs

A bill introduced Wednesday in the House would create an artificial joints database to root out bad practices and unnecessary surgeries, The New York Times reports. "The bill, co-sponsored by (Democrats) Bill Pascrell Jr. of New Jersey and Lloyd Doggett of Texas, would establish a government-backed registry to track patients" results over time and help detect ineffective surgical practices and faulty devices. Patient registries, in areas like orthopedics, are expected to play an important role in "comparative effectiveness" reviews that the Obama administration hopes will help identify which medical procedures and products work best." Surgeons" associations and makers of the joints say they support the idea of a registry, but would like to create one outside the scope of government, arguing it would be more effective. Advocates of registries say hundreds of millions of dollars are wasted on unnecessary surgeries. Device manufacturers have declined to finance the registries, stalling earlier attempts to create an independent registry by the American Academy of Orthopaedic Surgeons. The group has recently acquired funds to start up the registry but has yet to secure long-term financing. "Pascrell said he believed that patients had waited long enough for the group to act. He also said that it was important for the government to be involved, given deferred prosecution agreements reached a few years ago between the Justice Department and makers of artificial hips and knees after investigations of illegal kickbacks to surgeons to use their products" (Meier, 6/10). Meanwhile, the Federal Trade Commission said Thursday that protecting biotech drugs from generic versions for 12 to 14 years is unnecessary and that adding generic versions would drive down the cost of health care in the U.S., Reuters reports. "(A)n FTC report found "the 12- to 14-year regulatory exclusivity period is too long to promote innovation," particularly since brand-name companies "likely will retain substantial market share" after generic competitors are approved. The FTC report found that competitors would likely enter the market only for drugs that had more than $250 million in annual sales, and only two to three generic entrants would be expected" (6/10). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009